Start-Up Quarterly Statistics, Q2 2014
This article was originally published in Start Up
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.
You may also be interested in...
Series A Rounds H1 2014: Fewer Deals, Comparable Money
The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.
Roche Teams With Spero To Target Gram-Negative Pathogens
Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.
Deals In Depth: February 2023
Two $1bn+ alliances were penned in February. Topping the list was a potential $1.16bn deal between AstraZeneca and KYM Biosciences (a joint venture company of Keymed Biosciences and Lepu Biopharma, of which Keymed owns 70%). Under the exclusive global agreement, AstraZeneca will develop, manufacture and commercialize CMG901, a Phase I antibody drug conjugate for the treatment of Claudin 18.2-positive solid tumors including gastric cancers.